Lir Life SciencesBBCMF 15 EV-to-EBITDA is -5.30 as of Jul. 11, 2026. GuruFocus rates BBCMF with a GF Score™ of 15/100. Among 392 Biotechnology companies, Lir Life Sciences ranks worse than 255101.79% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lir Life Sciences's enterprise value is $8.86 Mil.
Lir Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Jan. 2026 was $-1.67 Mil. Therefore, Lir Life Sciences's EV-to-EBITDA for today is -5.30.
The historical rank and industry rank for Lir Life Sciences's EV-to-EBITDA or its related term are showing as below:
BBCMF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.73 Med: 0 Max: 0
Current: -4.73
BBCMF's EV-to-EBITDA is ranked worse than 100% of 392
companies
in the Biotechnology industry
Industry Median: 12.935
vs BBCMF: -4.73
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Lir Life Sciences (OTCPK:BBCMF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lir Life Sciences's PE Ratio (TTM) for today is calculated as:
Lir Life Sciences's share price for today is $0.05.
Lir Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.070.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Lir Life Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BBCMF vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Lir Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lir Life Sciences EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lir Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lir Life Sciences's EV-to-EBITDA falls into.
Lir Life Sciences's current Enterprise Value is $8.86 Mil.
Lir Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lir Life Sciences (BBCMF) has a EV-to-EBITDA of -5.30 as of Jul. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lir Life Sciences. According to the industry distribution chart, Lir Life Sciences ranks #999999 out of 392 companies in the Biotechnology industry.
Is Lir Life Sciences' EV-to-EBITDA too high?
Lir Life Sciences' current EV-to-EBITDA is -5.30. Based on the distribution chart, Lir Life Sciences ranks #999999 out of 392 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lir Life Sciences has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lir Life Sciences ranks #999999 out of 392 companies for EV-to-EBITDA. This places Lir Life Sciences in the lower half of its industry. The industry median EV-to-EBITDA is 12.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.94, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lir Life Sciences. For the Biotechnology industry, the median EV-to-EBITDA is 12.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lir Life Sciences's current EV-to-EBITDA is -5.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (BBCMF) has a current EV-to-EBITDA of -5.30. The current EV-to-EBITDA is -5.30. Lir Life Sciences' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Lir Life Sciences (BBCMF), the current EV-to-EBITDA is -5.30 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
15GF Score
Get the complete analysis for BBCMF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBCMF has been successfully added to your 